On July 17, Keymed Biosciences (02162.HK) fell 5.12% in regular trading, trading at HK$82.15/share, with turnover of HK$65.53 million.

The decline came amid a broad sell-off across the biotech sector, with the company's stock retreating after multiple positive catalysts were released in prior sessions. On July 15, the company issued a positive profit alert projecting H1 net profit of no less than RMB 1.2 billion, a turnaround from a RMB 79 million loss in the year-ago period. The same day, its TSLP/IL-13 bispecific antibody CM512 was proposed for breakthrough therapy designation. On July 16, Goldman Sachs increased its stake by 287,500 shares to 5.00%.

With these catalysts now absorbed, the broader biotech sector faced selling pressure. Among sector peers, Akeso fell 9.87%, 3SBio declined 9.38%, SKB Bio dropped 4.80%, Innovent Biologics lost 3.77%, and BeiGene slid 1.99%.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)